{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:51:53Z","timestamp":1760622713049},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,2,27]],"date-time":"2009-02-27T00:00:00Z","timestamp":1235692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00408-009-9138-6","type":"journal-article","created":{"date-parts":[[2009,2,26]],"date-time":"2009-02-26T22:47:01Z","timestamp":1235688421000},"page":"149-152","source":"Crossref","is-referenced-by-count":9,"title":["Stabilization of Lung Function and Clinical Symptoms in a Patient with Cystic Fibrosis (CF) After Institution of Infliximab: A Monoclonal Antibody that Binds Tumor Necrosis Factor alpha"],"prefix":"10.1007","volume":"187","author":[{"given":"Brian","family":"Casserly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Donat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,27]]},"reference":[{"issue":"8","key":"9138_CR1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","volume":"168","author":"RL Gibson","year":"2003","unstructured":"Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168(8):918\u2013951. doi: 10.1164\/rccm.200304-505SO","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"9138_CR2","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/thx.49.8.738","volume":"49","author":"RK Brown","year":"1994","unstructured":"Brown RK, Kelly FJ (1994) Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 49(8):738\u2013742. doi: 10.1136\/thx.49.8.738","journal-title":"Thorax"},{"issue":"15","key":"9138_CR3","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","volume":"336","author":"PJ Barnes","year":"1997","unstructured":"Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336(15):1066\u20131071. doi: 10.1056\/NEJM199704103361506","journal-title":"N Engl J Med"},{"issue":"6 Pt 1","key":"9138_CR4","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1164\/ajrccm.152.6.8520783","volume":"152","author":"TL Bonfield","year":"1995","unstructured":"Bonfield TL, Panuska JR, Konstan MW et al (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152(6 Pt 1):2111\u20132118","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"9138_CR5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm0598-615","volume":"4","author":"A Belaaouaj","year":"1998","unstructured":"Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN et al (1998) Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 4(5):615\u2013618. doi: 10.1038\/nm0598-615","journal-title":"Nat Med"},{"issue":"10","key":"9138_CR6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/13543784.15.10.1279","volume":"15","author":"SA Antoniu","year":"2006","unstructured":"Antoniu SA (2006) Etanercept for refractory asthma therapy. Expert Opin Investig Drugs 15(10):1279\u20131281. doi: 10.1517\/13543784.15.10.1279","journal-title":"Expert Opin Investig Drugs"},{"key":"9138_CR7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2005.09.006","volume":"25","author":"M Feldmann","year":"2005","unstructured":"Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN (2005) Anti-TNF therapy: where have we got to in 2005? J Autoimmun 25:26\u201328. doi: 10.1016\/j.jaut.2005.09.006 Suppl","journal-title":"J Autoimmun"},{"issue":"6149","key":"9138_CR8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/330662a0","volume":"330","author":"KJ Tracey","year":"1987","unstructured":"Tracey KJ, Fong Y, Hesse DG et al (1987) Anti-cachectin\/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330(6149):662\u2013664. doi: 10.1038\/330662a0","journal-title":"Nature"},{"issue":"1","key":"9138_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/rcmb.2006-0184TR","volume":"36","author":"C Guilbault","year":"2007","unstructured":"Guilbault C, Saeed Z, Downey GP, Radzioch D (2007) Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36(1):1\u20137. doi: 10.1165\/rcmb.2006-0184TR","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8457","key":"9138_CR10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0140-6736(85)92929-0","volume":"2","author":"HS Auerbach","year":"1985","unstructured":"Auerbach HS, Williams M, Kirkpatrick JA, Colten HR (1985) Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2(8457):686\u2013688. doi: 10.1016\/S0140-6736(85)92929-0","journal-title":"Lancet"},{"issue":"4","key":"9138_CR11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3476(95)70343-8","volume":"126","author":"H Eigen","year":"1995","unstructured":"Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV (1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 126(4):515\u2013523. doi: 10.1016\/S0022-3476(95)70343-8","journal-title":"J Pediatr"},{"issue":"13","key":"9138_CR12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","volume":"332","author":"MW Konstan","year":"1995","unstructured":"Konstan MW, Byard PJ, Hoppel CL, Davis PB (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332(13):848\u2013854. doi: 10.1056\/NEJM199503303321303","journal-title":"N Engl J Med"},{"issue":"11","key":"9138_CR13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200702-181OC","volume":"176","author":"MW Konstan","year":"2007","unstructured":"Konstan MW, Schluchter MD, Xue W, Davis PB (2007) Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176(11):1084\u20131089. doi: 10.1164\/rccm.200702-181OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"9138_CR14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccm.2007.02.002","volume":"28","author":"J Chmiel","year":"2007","unstructured":"Chmiel J, Konstan MW (2007) Inflammation and anti-Inflammatory therapies for cystic fibrosis. Clin Chest Med 28(2):331\u2013346. doi: 10.1016\/j.ccm.2007.02.002","journal-title":"Clin Chest Med"},{"issue":"4","key":"9138_CR15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/thx.2004.025262","volume":"60","author":"J Yarden","year":"2005","unstructured":"Yarden J, Radojkovic D, De Boeck K et al (2005) Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 60(4):320\u2013325. doi: 10.1136\/thx.2004.025262","journal-title":"Thorax"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-009-9138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-009-9138-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-009-9138-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T18:37:47Z","timestamp":1559068667000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-009-9138-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,27]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9138"],"URL":"https:\/\/doi.org\/10.1007\/s00408-009-9138-6","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,27]]}}}